AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KAUG 182 min read$COCP

Cocrystal Pharma, Inc. (COCP): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Cocrystal Pharma, Inc. (COCP) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) On August 12, 2026, the Board of Directors (the “Board”) of Cocrystal Pharma, Inc. (the “Company”) appointed Carol L. B

Original reporting
SEC EDGAR 8-K
Published Aug 18, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 8:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$COCP
Neutral
medium confidence
Mentioned
$COCP
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$COCPNeutralLow
01

Why it matters

The disclosure confirms a new director appointment effective immediately, with no related-party transactions requiring Item 404(a) disclosure.

02

Market read

This is a routine governance update. It may slightly influence sentiment, but it does not introduce new financial guidance, clinical, regulatory, or deal catalysts.

03

What to watch

Check for any concurrent committee assignments, compensation details, or follow-on filings (proxy/other 8-K items) that could make the appointment more material than it appears here.

Relevance 6/10Novelty 3/10Timing: filed Aug. 18, 2026, covering an Aug. 12 director appointment

Background

The company filed an SEC Form 8-K under Item 5.02 for director/officer changes and compensatory arrangements.

Company-level read

Ticker impact

$COCPNeutralMedium confidence
Context

Cocrystal Pharma appointed Carol L. Brosgart as a director effective immediately, disclosed in its Aug. 12, 2026 8-K.

Expected impact

Low likelihood of a sustained price move solely from this disclosure; any reaction is likely modest and short-lived.

Evidence & confidence

The filing discloses a new director appointment without related-party transactions or additional operational/financial commitments, so incremental information is limited.

Market effects

Sector

Minimal sector read-through; this is company-specific governance news.

Regional

No clear regional spillover expected.

Global

No direct global market relevance indicated.

Counterpoint

What could challenge this read

The appointment could be a precursor to broader strategic changes, but the 8-K provides no such details, so traders may be overreacting if they extrapolate.

Key entities

  • issuer
    Cocrystal Pharma, Inc.

    Nasdaq-listed company filing the 8-K for a director appointment.

  • person
    Carol L. Brosgart

    Appointed as a director effective immediately on Aug. 12, 2026.

  • officer
    James Martin

    CFO signing the filing.

Read at source← All news

Related articles

OCT 9
$COCPMedAI 8/10

H.C. Wainwright reiterates Cocrystal Pharma stock rating at buy

H.C. Wainwright reiterated a Buy rating and $6.00 price target for Cocrystal Pharma (COCP), citing progress in its norovirus drug trial. The stock is up 15% premarket. COCP's Phase 1b study for CDI-988 is ongoing, with primary endpoints focused on efficacy against norovirus. Analysts have varying price targets, ranging from $8 to $10. COCP also announced a new board member, Carol L. Brosgart, effective August 12, 2026.

investing.com1 min
OCT 16
$ASSTHigh

A 15% annual dividend accrues on $100 per share; payment depends on Strive's board declaring it.

Strive, Inc. (Nasdaq: ASST) priced its IPO of 7M shares, estimating gross proceeds of $700M. The company offers a 15% annual dividend on $100 per share, payable at the board's discretion. Strive focuses on structured finance and Bitcoin as a hurdle rate for capital deployment. Barclays and Cantor are joint book-running managers. The offering is pursuant to an SEC-registered prospectus.

stocktitan.net1 min
OCT 16
$XRPNHigh

XRP In Spotlight As Ripple CEO Brad Garlinghouse Reveals Bold Move At Evernorth Nasdaq Debut

Ripple CEO Brad Garlinghouse highlighted new XRP opportunities as Evernorth Holdings (XRPN) debuted on Nasdaq. Evernorth, backed by Ripple, aims to offer investors exposure to XRP through various strategies, including yield-generating products. The company holds 473 million XRP and raised $300 million in cash proceeds. Garlinghouse emphasized Ripple's ecosystem investments and multi-chain approach.

coingape.com2 min
OCT 15
$JPMMed

JPMorgan, Goldman Boost Yield on Volta AI Loan to Lure Investors

JPMorgan and Goldman Sachs increased the yield and improved terms on a $5 billion loan for AI cloud startup Volta Infrastructure, selling it at 6.5% above benchmark rates and 95 cents on the dollar. The loan, used to finance a Norway data center, includes investor protections and variable interest rates based on future credit ratings. The deal faced pushback from CLO managers due to its unrated status and market volatility.

finance.yahoo.com2 min
OCT 15
$IPMed

International Paper Evaluating Unsolicited Bidders for Its EMEA Packaging Business

International Paper (IP) is evaluating unsolicited bids for its EMEA Packaging Business, which operates in 30 countries. The company had previously planned to spin off this business, listing it on the London and New York stock exchanges. IP is now considering a potential sale alongside the spin-off, but no decision has been made. The EMEA Packaging Business includes both legacy DS Smith and IP assets.

paperage.com2 min